| ²é¿´: 273 | »Ø¸´: 3 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
[½»Á÷]
·ÒëÒ»¾ä»°
|
|||
|
Campillos et al. (2008) was the use of similarities in the sideeffects of known drugs to predict new drug-target interactions, some of which were verified by in vitro binding assays. The limitation of this approach is that it only applies to known side-effects of known drugs, thus limiting the ability of the method to perform high-throughput screening of potential interactions between new molecules and proteins. |
» ²ÂÄãϲ»¶
368»¯Ñ§Çóµ÷¼Á
ÒѾÓÐ13È˻ظ´
286Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
0703»¯Ñ§Çóµ÷¼Á
ÒѾÓÐ12È˻ظ´
µ÷¼Á
ÒѾÓÐ3È˻ظ´
²ÄÁϵ÷¼Á
ÒѾÓÐ13È˻ظ´
285Çóµ÷¼Á
ÒѾÓÐ18È˻ظ´
»úе¹¤³Ì313·ÖÕÒ¹¤¿Æµ÷¼Á
ÒѾÓÐ3È˻ظ´
¿¼Ñе÷¼Á-²ÄÁÏÀà-284
ÒѾÓÐ9È˻ظ´
Ò»Ö¾Ô¸ÏôóÉúÎïѧ332Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
±¾¿Æ211£¬293·ÖÇëÇóµ÷¼Á
ÒѾÓÐ13È˻ظ´
» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:
ÅÊÖ¦»¨Ñ§Ôº´óÁ¿ÕÐÊÕµ÷¼Á£º²ÄÁÏ¿ÆÑ§Ó빤³Ì(ѧ˶£º0805)ºÍ²ÄÁϹ¤³Ì£¨×¨Ë¶£º0856£©¡£
+1/187
î÷Îý»¯ºÏÎï°ëµ¼Ìå²ÄÁÏÓëÆ÷¼þÍŶÓ[ÍÆ½é]
+3/115
Ïã¸Û¿Æ¼¼´óѧ(¹ãÖÝ) CCUS¼°Îü¸½·ÖÀë·½ÏòÈ«½±²©Ê¿Éú£¬Äê½òÌù18Íò
+1/91
ר˶£¨×ÊÔ´Óë»·¾³¡¢ÍÁľˮÀû£©£¬½ÓÊÕ¿çרҵ£¬¹¤Ñ§¡¢Àíѧ¶¼ÐУ¡
+1/90
Õл¯Ñ§Ïà¹Ø×¨ÒµË¶Ê¿µ÷¼ÁÉú
+1/88
ÎïÀíѧ µ÷¼Á
+1/87
ÖйúË®²ú¿ÆÑ§Ñо¿Ôº»Æº£Ë®²úÑо¿ËùÕÅÐñÖ¾¿ÎÌâ×éÕÐÆ¸ ¿É´©´÷´«¸ÐÆ÷Ñо¿ ¿ÆÑÐÖúÀí
+1/85
ºÓÄϹ¤Òµ´óѧ»¯Ñ§»¯¹¤Ñ§Ôº 2026 Äê˶ʿµ÷¼ÁÕýÔÚ½øÐУ¡
+1/38
¸£½¨Àí¹¤´óѧÕÐÊÕ»·¾³¡¢»¯¹¤¡¢ÄÜÔ´¶¯Á¦¡¢ÐÂÄÜÔ´¿ÆÑ§Ó빤³Ì¡¢²ÄÁÏ¡¢»úеµÈѧ¿Æ±³¾°
+1/38
ÑÓ°²´óѧ»¯Ñ§Ó뻯¹¤Ñ§Ôº½ÓÊÕµ÷¼ÁÉú£¨»¯Ñ§¡¢»¯¹¤Ñ§Ë¶ºÍ²ÄÁÏÓ뻯¹¤×¨Ë¶£©
+5/35
¿¹²¡¶¾ÐÔ´«È¾²¡´´ÐÂÒ©ÎïÈ«¹úÖØµãʵÑéÊÒ¡ª½ÓÊÕ»¯Ñ§¡¢ÉúÎҩѧ¡¢ÉúÎïÓëÒ½Ò©µ÷¼Á¿¼Éú
+1/17
»¶Ó´ó¼Òµ÷¼Á----211´óÁ¬º£Ê´óѧ˫һÁ÷רҵ½ÓÊܵ÷¼Á
+1/11
¡¾²©Ê¿ÕÐÉú¡¿Î人¿Æ¼¼´óѧÕÐÊÕ²ÄÁÏ¡¢»¯¹¤¡¢»·¾³¡¢Ò±½ðÀà2026Äê¡°ÉêÇë-¿¼ºË¡±ÖƲ©Ê¿Éú
+1/11
̫ԿƼ¼´óѧ¹âѧ¹¤³Ì¡¢¹âµçÐÅÏ¢¹¤³Ì½ÓÊܵ÷¼Á
+1/10
Ïã¸Û¿Æ¼¼´óѧ »úÆ÷ÈË/ÉúÎïҽѧ
+1/9
²³º£´óѧ²ÄÁÏÓë»·¾³¹¤³ÌѧԺ·¢¹â¼°Í¸Ã÷ÌմɲÄÁÏ¡¢µØ¾ÛÎïÎü²¨»ìÄýÍÁ·½Ïò½ÓÊÕÑо¿Éúµ÷¼Á
+1/5
Î人·ÄÖ¯´óѧȫ¹úÖØµãʵÑéÊÒÂÀÓÀ¸Ö½ÌÊÚ¿ÎÌâ×éÕÐÊÕ²ÄÁÏ¡¢»¯Ñ§¡¢ÉúÎïÏà¹Ø×¨ÒµË¶Ê¿Ñо¿Éú
+1/4
Ð칤-»·¾³¹¤³ÌѧԺ-ÕÐÊÕµ÷¼Á˶ʿ
+1/4
2026Äê³¶«´óѧˮ²úרҵ¿¼Ñе÷¼Á-±õº£Éú̬¸ßµÈÑо¿Ôº
+1/2
Ò×¶ÈMFC¾«×¼¿ØÖÆÈ¼ÆøÁ÷Á¿£¬ÌáÉýȼÉÕϵͳЧÂÊÓëÎȶ¨ÐÔ
+1/2
8814402
ÖÁ×ðľ³æ (Ö°Òµ×÷¼Ò)
- ·ÒëEPI: 509
- Ó¦Öú: 18 (СѧÉú)
- ¹ó±ö: 0.381
- ½ð±Ò: 12916.1
- Ìû×Ó: 4183
- ÔÚÏß: 357.8Сʱ
- ³æºÅ: 1184404
4Â¥2011-03-04 11:12:58
8814402
ÖÁ×ðľ³æ (Ö°Òµ×÷¼Ò)
- ·ÒëEPI: 509
- Ó¦Öú: 18 (СѧÉú)
- ¹ó±ö: 0.381
- ½ð±Ò: 12916.1
- Ìû×Ó: 4183
- ÔÚÏß: 357.8Сʱ
- ³æºÅ: 1184404
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
pku123(½ð±Ò+1, ·ÒëEPI+1): 2011-03-04 09:37:38
pku123(½ð±Ò+1): 2011-03-05 07:32:19
ringzhu(½ð±Ò+16): ²»½âÊÍ~~ 2011-03-15 10:23:03
pku123(½ð±Ò+1, ·ÒëEPI+1): 2011-03-04 09:37:38
pku123(½ð±Ò+1): 2011-03-05 07:32:19
ringzhu(½ð±Ò+16): ²»½âÊÍ~~ 2011-03-15 10:23:03
|
Campillos et al. (2008) was the use of similarities in the side effects of known drugs to predict new drug-target interactions, some of which were verified by in vitro binding assays. The limitation of this approach is that it only applies to known side-effects of known drugs, thus limiting the ability of the method to perform high-throughput screening of potential interactions between new molecules and proteins. Campillos µÈ(2008)ÓÃÒ»Ö»Ò©ÎïµÄ¸±×÷ÓõÄÏàËÆÐÔÔ¤²âÐÂÒ©ºÍ°Ð±ê¼äµÄÏ໥×÷Óã¬ÆäÖÐһЩÏ໥×÷ÓÃÓÉÌåÄÚ½áºÏʹÓÃÈ·Ö¤¡£ÕâÖÖ·½·¨µÄ¾ÖÏÞÊÇËüÖ»Ó¦ÓÃÁËÒÑÖªÒ©ÎïµÄÒÑÖª¸±×÷Óã¬Òò´ËÏÞÖÆÁËÆäÔÚзÖ×Ӻ͵°°×ÖÊÖ®¼äDZÔÚÏ໥×÷ÓõĸßͨÁ¿É¸Ñ¡ÖеÄÓ¦Óᣠ|
2Â¥2011-03-04 09:37:04
8814402
ÖÁ×ðľ³æ (Ö°Òµ×÷¼Ò)
- ·ÒëEPI: 509
- Ó¦Öú: 18 (СѧÉú)
- ¹ó±ö: 0.381
- ½ð±Ò: 12916.1
- Ìû×Ó: 4183
- ÔÚÏß: 357.8Сʱ
- ³æºÅ: 1184404
3Â¥2011-03-04 09:38:04














»Ø¸´´ËÂ¥